PaxSafe's Mark Talens on why pharma supply chain AI fails before it starts — and the data foundry framework that changes that.
|Articles|May 3, 2016
IMS and Quintiles Announce Merger
Author(s)PharmExec Staff
Combined company will have market value of around $18 billion, reports Reuters.
Advertisement
Reuters
reported today that contract medical research provider Quintiles agreed to merge with healthcare information company IMS Health in a deal worth about $9 billion. The combined company will have a market value of nearly $18 billion and will offer drug and medical device makers services. After the deal, IMS Health shareholders will own about 51.4 percent of the combined company, while Quintiles shareholders will own the rest. The new company - Quintiles IMS Holdings Inc - will be led by IMS Health Chief Executive Ari Bousbib, while Quintiles CEO Tom Pike will be the vice chairman. The deal is expected to close in the second half of 2016. For more see here:
http://www.reuters.com/article/us-ims-hlth-hldg-m-a-quintiles-idUSKCN0XU0VO
Advertisement
Related to this article
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Why purpose is becoming the most important infrastructure in AI-driven health care technology.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
Advertisement
Advertisement
Trending on PharmExec
1
Prediction Markets Expose a Gap in Pharmaceutical Vendor Contracts
2
Roundup: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Therapy, Enodia Therapeutics Enters Collaboration and License Agreement to Develop Sec61-Targeting Small Molecules
3
The Manufacturing Issues That Continue to Contribute to Drug Shortages
4
Pharmaceutical Executive Daily: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Therapy with Roche
5